What Recent Fusion Literature Says About Osteobiologics and Bioactive Glass

The recent fusion literature is not short on biologic options. Autograft, allograft, DBM, ceramics, BMPs, cellular products, and newer synthetic materials all remain in play. What has changed over the past five years is the tone of the literature: less enthusiasm for one-size-fits-all claims, more emphasis on indication-specific use, cost, handling, and evidence quality. Recent reviews consistently note broad practice variation and limited head-to-head evidence across osteobiologic classes.

That makes bioactive glass an especially interesting category. It is not the most heavily marketed option in spine, and it does not carry the profile of rhBMP-2 or cell-based grafts. But recent reviews of synthetic grafts continue to highlight bioactive glass as a practical material with several advantages that fit current surgical and commercial realities: it is synthetic, off-the-shelf, osteoconductive, and compatible with workflow-focused, less-invasive procedures. 

Where bioactive glass fits in the current evidence

Bioactive glass should be viewed as a use-case-dependent osteobiologic, not a universal replacement for every graft strategy. A 2024 systematic review comparing osteobiologics in spine fusion concluded that evidence remains uneven across categories, with only limited studies specifically evaluating ceramics and bioactive glass. That same conclusion is echoed across broader reviews of spine biologics: there are many products, but relatively few high-quality comparative data sets. 

That said, the literature still gives bioactive glass a meaningful place in the conversation. A 2023 review of synthetic grafts in spinal fusion describes bioactive glass as part of the current generation of synthetic materials intended to improve fusion while avoiding some of the logistical and morbidity burdens of harvested autograft. It highlights the appeal of synthetics that are shelf-stable, standardized, and easier to integrate into modern surgical workflows. 

The practical advantages of bioactive glass

The advantages of bioactive glass are less about novelty and more about practicality.

First, it is synthetic and off the shelf. That matters because recent fusion literature increasingly frames biologic selection not only around fusion potential, but also around supply consistency, OR handling, and avoidance of donor-site morbidity. Bioactive glass avoids iliac crest harvest and the pain, time, and variability that come with it. 

Second, bioactive glass is attractive as an osteoconductive scaffold. Recent reviews describe its role as a material that supports bone apposition and can be used as a graft extender or substitute within broader fusion constructs. That makes it especially relevant in procedures where surgeons want a synthetic option that integrates with cages, local bone, or other graft materials rather than functioning as a standalone biologic bet. 

Third, bioactive glass aligns with workflow-conscious surgery. The current literature on synthetics repeatedly emphasizes the value of materials that are easier to store, simpler to prepare, and more consistent to deploy across cases. In a less-invasive environment, where access is constrained and efficiency matters, those characteristics are not secondary—they are part of the clinical value proposition. 

What the literature says about performance

The strongest caution in the literature is that bioactive glass should not be oversold as universally equivalent to autograft in all forms. The best available synthesis specific to spine found that across clinical studies, fusion was seen in 84% of patients treated with bioactive glass overall. In subgroup analysis, bioactive glass mixed with local autograft showed fusion rates similar to standalone autograft, while standalone bioactive glass substrates performed worse than autograft alone. 

That distinction matters. It suggests that the advantage of bioactive glass may be greatest when it is used as part of a composite strategy rather than as a solitary replacement material. For surgeons, that is a familiar pattern: the right carrier, the right extender, and the right local biology often matter more than the label on any single graft product. 

Recent lumbar fusion reviews also reflect this balanced position. A 2024 review of implants and bone graft types for lumbar fusion described bioglass as promising, but still under investigation, with ongoing questions around dosing, absorption behavior, and clinical positioning. That is not a negative signal so much as a sign of maturation: the field is moving from broad optimism to more disciplined product selection. 

What recent fusion literature really supports

So what does the last five years of fusion literature actually support?

It supports the view that osteobiologics should be selected more deliberately, with closer attention to indication, workflow, cost, and evidence quality. It supports the idea that synthetic options have a durable place in spine fusion. And it supports bioactive glass as a credible part of that synthetic category—particularly where the goal is to avoid harvest morbidity, use a shelf-stable material, and build a fusion environment with a practical graft extender or scaffold. 

Bioactive glass appears most compelling when used in a selection-based strategy, often in combination constructs, where its handling, availability, and osteoconductive properties can provide real procedural and clinical value. 

References

1. Haws BE, Khechen B, Guntin JA, et al. Advances in synthetic grafts in spinal fusion surgery. J Clin Med. 2023. 

2. Tan LA, Straus DC, Traynelis VC. Comparison of different osteobiologics in terms of surgical characteristics and clinical efficacy in spine fusion surgery. Global Spine J. 2024. 

3. Gadjradj PS, Harhangi BS. Biologics in spine fusion. Neurosurg Clin N Am. 2023. 

4. Rhee JM, Yoon ST, Kim HJ, et al. Advances in implants and bone graft types for lumbar spinal fusion: a narrative review. J Clin Med. 2024. 

5. Katsuura Y, Mahar AT, Buser Z, Wang JC. The effect of bioactive glasses on spinal fusion: a cross-disciplinary systematic review and meta-analysis of the preclinical and clinical data. Bone Joint Res. 2020;9(7):445-457.